Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System
Sign Up to like & getrecommendations! Published in 2019 at "Targeted Oncology"
DOI: 10.1007/s11523-019-00632-w
Abstract: BackgroundImmune checkpoint inhibitors (ICIs), including antibodies targeting cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death 1 or its ligand (PD1/PDL1), elicit different immune-related adverse events (irAEs), but their global safety is incompletely characterized.ObjectiveThe… read more here.
Keywords: reporting; checkpoint inhibitors; disproportionality; pd1 pdl1 ... See more keywords
Anti-PD1/PDL1 induced psoriasis.
Sign Up to like & getrecommendations! Published in 2017 at "Current problems in cancer"
DOI: 10.1016/j.currproblcancer.2017.10.003
Abstract: BACKGROUND Immune checkpoint inhibitors are novel agents approved for the treatment of late-stage malignancies. Despite its important clinical benefits, checkpoint inhibition is associated with a unique spectrum of side effects known as immune-related adverse events.… read more here.
Keywords: psoriasis; treatment; anti pd1; pd1 pdl1 ... See more keywords
Les inhibiteurs de PD1 et PDL1 peuvent-ils être utilisés sans risque dans la fibrose pulmonaire idiopathique ?
Sign Up to like & getrecommendations! Published in 2018 at "Revue Des Maladies Respiratoires"
DOI: 10.1016/j.rmr.2017.10.252
Abstract: Introduction Bien que les inhibiteurs de PD1 et PDL1 aient un meilleur profil de tolerance que la chimiotherapie, ils peuvent induire des manifestations inflammatoires ou auto-immunes dont des pneumopathies interstitielles diffuses (PID) parfois severes. Dans les essais… read more here.
Keywords: inhibiteurs pd1; cancer bronchique; les inhibiteurs; pd1 pdl1 ... See more keywords
MicroRNA-223: a key regulator of liver tumour microenvironment
Sign Up to like & getrecommendations! Published in 2023 at "Gut"
DOI: 10.1136/gutjnl-2022-329322
Abstract: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancerrelated deaths worldwide with few effective drug treatments. Recent combination therapies inhibiting immune checkpoints and angiogenesis showed better overall and progressionfree survival outcomes than the protein… read more here.
Keywords: hcc; expression; pd1 pdl1; mir223 ... See more keywords
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003625
Abstract: Background There is great interest in finding ways to identify patients who will develop toxicity to cancer therapies. This has become especially pressing in the era of immune therapy, where toxicity can be long-lasting and… read more here.
Keywords: cancer; pd1 pdl1; anti pd1; therapy ... See more keywords
Abstract 3313: A novel RNA aptamer-based assay for quantifying fractional occupancy of PD1 by PDL1 in formalin fixed biospecimens
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3313
Abstract: Background: There is a need for better prognostic biomarkers for PD1-based therapy. Quantifying the fractional occupancy (FO) of PD1 by PDL1, and PDL1 by PD1, in tumor can be a potential biomarker. We previously reported… read more here.
Keywords: occupancy; pdl1; formalin fixed; pd1 pdl1 ... See more keywords
Abstract 970: Clinical analysis of patients (pts) with lung cancer treated with anti-PD1/PDL1 therapy
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-970
Abstract: Background: Characterization of Lung cancer treated with anti-PD1/PDL1 therapy was approach to predict the clinical benefit. This research is a prospective and observational study of long-term immunization therapy safety in routine clinical practice in lung… read more here.
Keywords: lung cancer; pdl1 therapy; anti pd1; therapy ... See more keywords
Analysis of response rate with anti-PD1/PDL1 antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials (RCT).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14576
Abstract: e14576Background: Anti-PD1/PDL1 antibodies (mAbs) have been shown to increase overall survival (OS) compared to standard of care (SOC) in solid tumors (mainly melanoma and lung cancer). Despite the efficacy in OS, a significant proportion of… read more here.
Keywords: anti pd1; solid tumors; response; pd1 pdl1 ... See more keywords
Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.6_suppl.454
Abstract: 454Background: Identification of biomarkers predictive of response to ICI could help guide treatment (tx) decisions. We assessed the correlation between PD1/PDL1 expression in key immunomodulatory subsets (myeloid-derived suppressor cells [MDSC]; CD8+ T cells) and tx… read more here.
Keywords: response; pd1 pdl1; pdl1 expression; mdsc ... See more keywords
Immune-related adverse events for different age groups using the FDA Adverse Event Reporting System.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e14256
Abstract: e14256 Background: Understanding immune-related adverse events (irAEs) for different age groups is crucial in the era of immunotherapy. The aim of our study is to assess the irAE profiles in different age groups (≤65 and… read more here.
Keywords: age groups; different age; combination; pd1 pdl1 ... See more keywords
Clinical Significance of PD1 and PDL1 in Human Breast Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Anticancer research"
DOI: 10.21873/anticanres.11817
Abstract: BACKGROUND/AIM Programmed death 1 (PD1) and its ligand programmed death ligand 1 (PDL1) form a pathway which when activated is thought to result in suppression of antitumor adaptive responses, influencing antitumor immunity. With potential targeted… read more here.
Keywords: pd1 pdl1; breast cancer; pdl1;